1、INTEGRATED ANNUAL REPORT 2024INTEGRATED ANNUAL REPORT2024Introduction3Letter from the CEO4Highlights6Milestones in 20247Sustainability Statement8General9Environment28Social87Governance180Sustainable growth 211Financial Performance212Grifols value creation221Taxation224Annexes228Indices of content ac

2、cording to regulations229Indices of content according to voluntary indices241Methodologies251NON-GAAP measures reconciliation255Glossary and abbreviations257Independent Review Report260Index123Integrated Annual Report 20244IntroductionSustainability StatementSustainable growthAnnexesLetter from the

3、CEOIn a year of overcoming challenges,marked by our conviction in our companys project,I am pleased to report on Grifols strong financial results,key operational and strategic milestones,as well as sustainability achievements in 2024.As I approach my one-year anniversary,I could not be prouder and g

4、rateful to lead a company with the clear mission to improve the lives of patients around the world.Being part of a dedicated team that is as outstanding as the plasma-based medicines and solutions we produce is truly inspiring.Throughout the year,we have maintained our unwavering commitment to susta

5、inable growth,innovation,sustainability and long-term value creation.In 2024,we achieved record revenues of Euros 7.2 billion,a 10%increase over the prior year.This result reflects our success in operating in a market with high growth potential and meeting the robust global demand for plasma protein

6、s,in particular with our immunoglobulin franchise.Numerous milestones point the way for Grifols continued sustainable growth.Operational transformation across our plasma operationsIn 2024 we took further steps to strengthen Grifols competitiveness.We continued to optimize our network of more than 40